Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Mylan
Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-134244 · Präparat HOS-097542
18 Medicinal product by Effects on drug Recommendation concerning therapeutic areas levels co-administration with Mean percent emtricitabine/tenofovir disoproxil change in AUC, (emtricitabine 200 mg, tenofovir disoproxil Cmax, Cmin with 245 mg) 90% confidence intervals if available (mechanism) Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations of tenofovir (400 mg/100 mg q.d.) + AUC: ↔ resulting from co-administration of tenofovir Atazanavir/Ritonavir Cmax: ↔ disoproxil, sofosbuvir/velpatasvir and (300 mg q.d./100 mg q.d.) + atazanavir/ritonavir may increase adverse Emtricitabine/Tenofovir disoproxil reactions related to tenofovir disoproxil, (200 mg/245 mg q.d.) GS-3310072: including renal disorders. The safety of AUC: ↔ tenofovir disoproxil when used with Cmax: ↔ sofosbuvir/velpatasvir and a pharmacokinetic Cmin: ↑ 42% (↑ 37 enhancer (e.g. ritonavir or cobicistat) has not to ↑ 49) been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) velpatasvir (HOS-108929) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-03T14:25:00Z · SHA-256 dca28001b5f37f5fac24ef504bb45938e413f238844fb60b012f3f9b5a32b40c · Passage f0ad9bf57f022835346b2792c561cde123503c18924852d4dee05e2d705e1c50 · Zeichen 24083–25681 im Abschnitt